1. Home
  2. SSTK vs RIGL Comparison

SSTK vs RIGL Comparison

Compare SSTK & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shutterstock Inc.

SSTK

Shutterstock Inc.

HOLD

Current Price

$17.34

Market Cap

675.2M

Sector

Technology

ML Signal

HOLD

Logo Rigel Pharmaceuticals Inc.

RIGL

Rigel Pharmaceuticals Inc.

HOLD

Current Price

$34.29

Market Cap

683.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSTK
RIGL
Founded
2003
1996
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
675.2M
683.2M
IPO Year
2012
2000

Fundamental Metrics

Financial Performance
Metric
SSTK
RIGL
Price
$17.34
$34.29
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$25.00
$43.20
AVG Volume (30 Days)
273.8K
287.6K
Earning Date
02-24-2026
03-03-2026
Dividend Yield
8.34%
N/A
EPS Growth
66.87
2698.26
EPS
1.69
6.20
Revenue
$1,020,010,000.00
$282,076,000.00
Revenue This Year
$11.41
$66.37
Revenue Next Year
N/A
N/A
P/E Ratio
$10.25
$5.54
Revenue Growth
13.06
79.13
52 Week Low
$14.35
$15.50
52 Week High
$29.96
$52.24

Technical Indicators

Market Signals
Indicator
SSTK
RIGL
Relative Strength Index (RSI) 39.92 43.10
Support Level $17.83 $33.23
Resistance Level $19.34 $34.99
Average True Range (ATR) 0.92 1.46
MACD -0.19 0.15
Stochastic Oscillator 0.76 43.31

Price Performance

Historical Comparison
SSTK
RIGL

About SSTK Shutterstock Inc.

Shutterstock Inc is a U.S.-based company that is engaged in the provision of digital content. The content segment, whose offerings include licenses for Images, Footage, Music, 3 Dimensional, and Generative AI content. Data, Distribution, and Service offerings address customer demand for products and services that are beyond its Content licenses. The company generates the majority of its revenue from Content offerings. Geographically the company generates the majority of its revenue from the Domestic market, but also has its presence in Europe and Rest of the Countries.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: